logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
H

Haruhiro Saito

Kanagawa Cancer Center
H指数:31
被引数:6,711

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-World Outcomes and Early Progressive Disease Analysis of Nivolumab and Ipilimumab Combination Therapy in Metastatic NSCLC: LIGHT-NING Study 2.5-year update

真实世界结局和早期进展性疾病分析：纳武利尤单抗联合伊匹木单抗治疗转移性非小细胞肺癌的LIGHT-NING研究2.5年更新

Clinical Lung Cancer
IF3.3
2026-10-130
OAAI
Hisao Imai; Teppei Yamaguchi; Koichi Azuma; Takashi Kijima; Yukihiro Toi; Kazuma Kishi; Kohei Fujita; Haruhiro Saito; Yoshimasa Shiraishi; Junko Tanizaki; Yuta Takashima; Yuichi Tambo; Satoshi Watanabe; Osamu Hataji; Tatsuro Fukuhara; Tomoyuki Ohsugi; Yu Tobishima; Hidehito Horinouchi
Gut microbiome functional pathways outperform taxonomic profiles in predicting immune checkpoint inhibitor response in non-small cell lung cancer: an interpretable machine learning approach with SHAP

肠道微生物组功能通路在预测非小细胞肺癌免疫检查点抑制剂应答方面优于分类谱：一种可解释的机器学习方法与SHAP

Frontiers in Immunology
IF5.9
2026-05-150
OAAI
FW Feifei Wei; YN Yoshiro Nakahara; JI Junya Isobe; YI Yuka Igarashi; HS Haruhiro Saito; SM Shuji Murakami; TK Tetsuro Kondo; HH Hidetomo Himuro; TK Taku Kouro; TM Tomoya Matsui; SW Satoshi Wada; TT Takuya Tsunoda; KY Kiyoshi Yoshimura †; TS Tetsuro Sasada †
Final overall survival analysis of the APPLE study: atezolizumab and platinum-pemetrexed with or without bevacizumab for metastatic nonsquamous non-small cell lung cancer

APPLE研究最终总生存期分析：阿替利珠单抗联合含铂培美曲塞方案，伴或不伴贝伐珠单抗治疗转移性非鳞非小细胞肺癌

Lung Cancer
IF4.4
2026-05-080
OAAI
Yoshimasa Shiraishi; Junji Kishimoto; Shunichi Sugawara; Hideaki Mizutani; Haruko Daga; Koichi Azuma; Hirotaka Matsumoto; Osamu Hataji; Kazumi Nishino; Masahide Mori; Takehito Shukuya; Haruhiro Saito; Motoko Tachihara; Kaoru Tanaka; Asuka Tsuya; Kazushige Wakuda; Noriko Yanagitani; Tomohiro Sakamoto; Junko Baba; Akito Hata
Machine learning–based insights into circulating autoantibody dynamics and treatment outcomes in patients with NSCLC receiving immune checkpoint inhibitors

基于机器学习的循环自身抗体动力学和治疗结局在NSCLC接受免疫检查点抑制剂治疗患者中的洞察

Frontiers in Immunology
IF5.9
2025-10-030
OAAI
Feifei Wei‡; Hiroyuki Takeda‡; Koichi Azuma‡; Yoshiro Nakahara; Yuka Igarashi; Kenta Murotani; Haruhiro Saito; Shuji Murakami; Tetsuro Kondo; Taku Kouro; Hidetomo Himuro; Kayoko Tsuji; Mitsuru Komahashi; Tatsuya Sawasaki†; Tetsuro Sasada†
Multi-omics analysis-based clinical and functional significance of a novel prognostic and immunotherapeutic gene signature derived from amino acid metabolism pathways in lung adenocarcinoma

基于多组学分析的肺腺癌氨基酸代谢通路新的预后和免疫治疗基因标签的临床和功能意义

FRONTIERS IN IMMUNOLOGY
IF5.9
2024-12-131
OAAI
Xiang, Huihui; Kasajima, Rika; Azuma, Koichi; Tagami, Tomoyuki; Hagiwara, Asami; Nakahara, Yoshiro; Saito, Haruhiro; Igarashi, Yuka; Wei, Feifei; Ban, Tatsuma; Yoshihara, Mitsuyo; Nakamura, Yoshiyasu; Sato, Shinya; Koizume, Shiro; Tamura, Tomohiko; Sasada, Tetsuro; Miyagi, Yohei
Prognostic Significance of Plasma Neutrophil Extracellular Trap Levels in Patients with Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors

血浆中性粒细胞胞外诱捕网水平对接受免疫检查点抑制剂治疗的非小细胞肺癌患者的预后意义

BIOMEDICINES
IF3.9
2024-08-120
OAAI
Horaguchi, Shun; Nakahara, Yoshiro; Igarashi, Yuka; Kouro, Taku; Wei, Feifei; Murotani, Kenta; Udagawa, Seiichi; Higashijima, Naoko; Matsuo, Norikazu; Murakami, Shuji; Kato, Terufumi; Kondo, Tetsuro; Xiang, Huihui; Kasajima, Rika; Himuro, Hidetomo; Tsuji, Kayoko; Mano, Yasunobu; Komahashi, Mitsuru; Miyagi, Yohei; Saito, Haruhiro; Azuma, Koichi; Uehara, Shuichiro; Sasada, Tetsuro
A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study

Durvalumab加或不加Tremelimumab联合化疗作为转移性非小细胞肺癌一线治疗的简要报告: POSEIDON 3期研究中肿瘤PD-L1表达的结果

CLINICAL LUNG CANCER
IF3.3
2024-05-013
OAAI
Garon, Edward B.; Cho, Byoung Chul; Luft, Alexander; Alatorre-Alexander, Jorge; Geater, Sarayut Lucien; Trukhin, Dmytro; Kim, Sang -We; Ursol, Grygorii; Hussein, Maen; Lim, Farah Louise; Yang, Cheng-Ta; Araujo, Luiz Henrique; Saito, Haruhiro; Reinmuth, Niels; Kohlmann, Milena; Lowery, Caitlin; Mann, Helen; Peters, Solange; Mok, Tony S.; Johnson, Melissa L.
A Phase Study of Ubenimex Combined With Pembrolizumab, Nab-Paclitaxel, and Carboplatin for Previously Untreated Advanced Squamous Non-Small-Cell Lung Cancer: TORG2241 (UBE-Q)
CLINICAL LUNG CANCER
IF3.3
2024-01-011
OAAI
Nakamichi, Shinji; Kubota, Kaoru; Matsuyama, Kotone; Misumi, Toshihiro; Kozuki, Toshiyuki; Sugawara, Shunichi; Naoki, Katsuhiko; Kobayashi, Nobuaki; Shukuya, Takehito; Shimokawa, Tsuneo; Ishihara, Masashi; Wakui, Hiroshi; Hosomi, Yukio; Tanaka, Hiroshi; Saito, Haruhiro; Hosokawa, Shinobu; Takiguchi, Yuichi; Kasai, Takashi; Nokihara, Hiroshi; Morita, Ryo; Aono, Hiromi; Furuya, Naoki; Okamoto, Hiroaki
LIGHT-NING 2nd interim analysis: Early safety of 1L nivolumab plus ipilimumab plus /- chemotherapy for NSCLC in Japan
ANNALS OF ONCOLOGY
IF65.4
2023-11-011
OA
Azuma, Koichi; Imai, Hisao; Kijima, Takashi; Kishi, Kazuma; Saito, Haruhiro; Yamaguchi, Teppei; Hayashi, Hidetoshi; Shiraishi, Yoshimasa; Fujita, Kohei; Watanabe, Satoshi; Kitazono, Satoru; Fukuhara, Tatsuro; Hataji, Osamu; Toi, Yukihiro; Mizutani, Hideaki; Hamakawa, Yusuke; Maemondo, Makoto; Ohsugi, Tomoyuki; Suzuki, Keisuke; Horinouchi, Hidehito; Ohe, Yuichiro
NOTCH1 and CREBBP co-mutations negatively affect the benefit of adjuvant therapy in completely resected EGFR-mutated NSCLC: translational research of phase III IMPACT study
MOLECULAR ONCOLOGY
IF4.5
2023-10-283
OA
Ikeda, Satoshi; Tsuboi, Masahiro; Sakai, Kazuko; Misumi, Toshihiro; Akamatsu, Hiroaki; Shoda, Hiroyasu; Sakakura, Noriaki; Nakamura, Atsushi; Ohde, Yasuhisa; Hayashi, Hidetoshi; Okishio, Kyoichi; Okada, Morihito; Yoshino, Ichiro; Okami, Jiro; Takahashi, Kazuhisa; Ikeda, Norihiko; Tanahashi, Masayuki; Tambo, Yuichi; Saito, Haruhiro; Toyooka, Shinichi; Inokawa, Hidetoshi; Chen-Yoshikawa, Toyofumi; Yokoyama, Toshihide; Okamoto, Tatsuro; Yanagitani, Noriko; Oki, Masahide; Takahama, Makoto; Sawa, Kenji; Tada, Hirohito; Nakagawa, Kazuhiko; Mitsudomi, Tetsuya; Nishio, Kazuto

研究方向

暂未获取到该数据
S
Shuji Murakami
H 指数:36论文数:324被引数:1.5万
H
Hiroyuki Ito
H 指数:42论文数:383被引数:8,324
T
Tetsuro Kondo
H 指数:23论文数:209被引数:2,628
T
Tomoyuki Yokose
H 指数:0论文数:0被引数:6
T
Tetsuya Isaka
H 指数:13论文数:90被引数:559
F
Fumihiro Oshita
H 指数:28论文数:191被引数:2,922
K
Kouzo Yamada
H 指数:24论文数:179被引数:2,328
H
Haruhiko Nakayama
H 指数:45论文数:376被引数:7,147
Y
Yohei Miyagi
H 指数:58论文数:640被引数:1.2万
K
Koichi Azuma
H 指数:53论文数:537被引数:1.3万